U.S. FDA delays decision on Regeneron/Roche COVID antibody therapy – Reuters

U.S. FDA delays decision on Regeneron/Roche COVID antibody therapy – Reuters

The Regeneron Pharmaceuticals company logo is seen on a building at the company’s Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Brendan McDermid
April 14 (Reuters) – The U.S. Food and Drug Administration has extended by three months its review of Regeneron Pharmaceuticals Inc’s (REGN.O) application for the full approval of its COVID-19 antibody therapy, the U.S. drugmaker said on Thursday.
Before making its decision, the health agency wants to look at additional data submitted by Regeneron on using the antibody cocktail as a preventive treatment.
The FDA has not asked for any extra studies to complete its review and will now decide on the drug by July 13, Regeneron said.
Regeneron’s "cocktail" of two monoclonal antibodies, casirivimab and imdevimab, had received an emergency use authorization in the United States in late 2020 to treat patients who were 12 years and older with mild-to-moderate COVID-19.
The therapy, called REGEN-COV, was later also authorized in the country for the prevention of COVID-19 in certain people exposed to an infected individual, or who were at high risk of such exposure.
However, data showed that REGEN-COV and a rival monoclonal antibody drug from Eli Lilly (LLY.N) were unlikely to be effective against the highly contagious Omicron coronavirus variant. That led the U.S. FDA to revise the emergency use authorizations for both therapies to limit their use. read more
Regeneron is collaborating with Roche (ROG.S), which is primarily responsible for the development and distribution of the treatment outside the United States.
Our Standards: The Thomson Reuters Trust Principles.
Sign up to our health newsletter to keep up with the latest healthcare trends and pharmaceutical news.
Subscribe to our newsletter to get all the news you need to start your day.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world’s media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved

source


Leave a Reply

Your email address will not be published.